Plain-English translation of NCT06249191 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new antibody drug, combined with a standard chemotherapy regimen called DA EPOCH in people with aggressive, untreated lymphomas. The study wants to see if this combination is safe and whether it helps patients achieve complete remission. The trial has two parts: first, researchers will carefully watch for side effects and safety; then, they'll focus on how well the treatment actually works.
Aggressive B-cell lymphomas with a specific genetic change (c-Myc rearrangement) are hard to treat and patients often don't survive as long as doctors hope. This medication is designed to help the immune system better recognize and destroy cancer cells, and combining it with proven chemotherapy might give patients a better chance of recovery.
You likely qualify if…
You likely don't qualify if…
You will receive the medication and chemotherapy in repeating 3-week cycles for up to 6 cycles. During cycle 1, you'll get the antibody medication three times; in later cycles, you'll receive it once. You'll also receive four chemotherapy drugs over the first 4–5 days of each cycle, plus oral medication at home. Throughout the study, you'll have blood tests, imaging scans (CT, PET, or MRI), heart monitoring, and possibly bone marrow biopsies. After treatment ends, you'll have follow-up visits every 3 months for 2 years, then every 6 months.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States